Farallon Capital Management LLC Grows Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

Farallon Capital Management LLC raised its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 21.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,428,167 shares of the company's stock after purchasing an additional 785,578 shares during the quarter. Farallon Capital Management LLC owned 4.38% of Biohaven worth $165,392,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Spire Wealth Management purchased a new stake in shares of Biohaven during the fourth quarter valued at approximately $56,000. Amalgamated Bank increased its position in shares of Biohaven by 21.9% during the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company's stock valued at $109,000 after acquiring an additional 527 shares during the last quarter. US Bancorp DE increased its position in shares of Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after acquiring an additional 798 shares during the last quarter. Quarry LP purchased a new stake in shares of Biohaven during the fourth quarter valued at approximately $112,000. Finally, Elkhorn Partners Limited Partnership increased its position in shares of Biohaven by 50.0% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,300 shares of the company's stock valued at $123,000 after acquiring an additional 1,100 shares during the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Robert W. Baird decreased their price target on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a research report on Monday, April 28th. HC Wainwright reissued a "buy" rating and issued a $54.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. William Blair raised Biohaven to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, JPMorgan Chase & Co. decreased their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Fourteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $62.54.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs acquired 32,700 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, with a total value of $996,369.00. Following the completion of the purchase, the director now owns 2,320,571 shares of the company's stock, valued at approximately $70,707,798.37. This represents a 1.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 16.00% of the stock is owned by corporate insiders.

Biohaven Price Performance

Shares of Biohaven stock traded down $0.05 during trading hours on Friday, reaching $20.20. The company had a trading volume of 1,105,302 shares, compared to its average volume of 1,170,277. Biohaven Ltd. has a one year low of $15.79 and a one year high of $55.70. The business has a fifty day simple moving average of $23.44 and a 200 day simple moving average of $35.24. The firm has a market cap of $2.06 billion, a PE ratio of -2.16 and a beta of 1.18.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). On average, research analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.